Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit.
作者信息
Gordeuk Victor R, Miasnikova Galina Y, Sergueeva Adelina I, Lorenzo Felipe R, Zhang Xu, Song Jihyun, Stockton David W, Prchal Josef T
机构信息
Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
Chuvash Republic Clinical Hospital, Cheboksary, Russia.
出版信息
Haematologica. 2020 Mar;105(3):e87-e90. doi: 10.3324/haematol.2019.216267. Epub 2019 Jul 9.
Abstract
摘要
相似文献
1
Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit.
Haematologica. 2020 Mar;105(3):e87-e90. doi: 10.3324/haematol.2019.216267. Epub 2019 Jul 9.
2
Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
Haematologica. 2019 Apr;104(4):653-658. doi: 10.3324/haematol.2018.210732. Epub 2019 Mar 14.
3
Congenital erythrocytosis with elevated erythropoietin level: an incorrectly set "erythrostat"?
J Pediatr Hematol Oncol. 1998 Nov-Dec;20(6):560-2.
4
Idiopathic erythrocytosis: a disappearing entity.
Hematology Am Soc Hematol Educ Program. 2009:629-35. doi: 10.1182/asheducation-2009.1.629.
5
Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis.
Int J Lab Hematol. 2019 Apr;41(2):162-167. doi: 10.1111/ijlh.12949. Epub 2018 Dec 3.
6
Genetic basis of congenital erythrocytosis: mutation update and online databases.
Hum Mutat. 2014 Jan;35(1):15-26. doi: 10.1002/humu.22448. Epub 2013 Oct 22.
7
Congenital erythrocytosis - A condition behind recurrent thromboses: A case report and literature review.
Clin Hemorheol Microcirc. 2021;79(3):417-421. doi: 10.3233/CH-211120.
8
Congenital erythrocytosis: a new form associated with an erythropoietin-dependent mechanism.
Br J Haematol. 1980 Jan;44(1):17-24. doi: 10.1111/j.1365-2141.1980.tb01179.x.
9
Genetic basis of congenital erythrocytosis.
Int J Lab Hematol. 2018 May;40 Suppl 1:62-67. doi: 10.1111/ijlh.12828.
10
Congenital erythrocytosis.
Int J Lab Hematol. 2016 May;38 Suppl 1:59-65. doi: 10.1111/ijlh.12506. Epub 2016 May 9.
引用本文的文献
1
Increased occurrence of migraine aura and susceptibility to spreading depolarizations at altitude.
medRxiv. 2025 Aug 13:2025.08.09.25333153. doi: 10.1101/2025.08.09.25333153.
2
Repurposing of NKA inhibitors ('cardiac glycosides'): a critical analysis.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 18. doi: 10.1007/s00210-025-04443-x.
3
Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs.
Endocr Connect. 2025 Jun 21;14(6). doi: 10.1530/EC-24-0695. Print 2025 Jun 1.
4
[Familial erythrocytosis type 2 due to VHL germline mutations: a case report and literature review].
Zhonghua Xue Ye Xue Za Zhi. 2025 Jan 14;46(1):75-80. doi: 10.3760/cma.j.cn121090-20241011-00390.
5
Increased Transferrin Concentrations Are Not Associated With Thrombosis in People Living at High Altitude.
J Hematol. 2025 Feb;14(1):20-25. doi: 10.14740/jh1388. Epub 2025 Jan 17.
6
Impact of mutations on thrombotic risk in patients with idiopathic erythrocytosis: A single-centre study.
EJHaem. 2024 Oct 4;5(5):1086-1088. doi: 10.1002/jha2.1019. eCollection 2024 Oct.
7
Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?
Endocr Connect. 2024 Sep 28;13(10). doi: 10.1530/EC-24-0283. Print 2024 Oct 1.
8
Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α.
Am J Physiol Lung Cell Mol Physiol. 2024 Oct 1;327(4):L503-L519. doi: 10.1152/ajplung.00077.2024. Epub 2024 Aug 19.
9
syndrome-related congenital polycythemia and response to belzutifan.
Haematologica. 2024 Dec 1;109(12):4145-4147. doi: 10.3324/haematol.2024.285724.
10
Are coagulation profiles in Andean highlanders with excessive erythrocytosis favouring hypercoagulability?
Exp Physiol. 2024 Jun;109(6):899-914. doi: 10.1113/EP091670. Epub 2024 Mar 30.
本文引用的文献
1
HIF-2α-pVHL complex reveals broad genotype-phenotype correlations in HIF-2α-driven disease.
Nat Commun. 2018 Aug 22;9(1):3359. doi: 10.1038/s41467-018-05554-1.
2
Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia.
Haematologica. 2017 May;102(5):e166-e169. doi: 10.3324/haematol.2016.158170. Epub 2017 Jan 19.
3
EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells.
Biochim Biophys Acta. 2016 Apr;1862(4):670-678. doi: 10.1016/j.bbadis.2016.01.017. Epub 2016 Jan 26.
4
Complications in children and adolescents with Chuvash polycythemia.
Blood. 2015 Jan 8;125(2):414-5. doi: 10.1182/blood-2014-10-604660.
5
Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing.
Blood Cells Mol Dis. 2014 Jan;52(1):35-45. doi: 10.1016/j.bcmd.2013.07.016. Epub 2013 Aug 28.
6
Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.
Blood. 2013 May 9;121(19):3918-24. doi: 10.1182/blood-2012-11-469296. Epub 2013 Mar 28.
7
The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W).
Haematologica. 2013 Apr;98(4):560-7. doi: 10.3324/haematol.2012.070508. Epub 2013 Feb 12.
8
Decreased serum glucose and glycosylated hemoglobin levels in patients with Chuvash polycythemia: a role for HIF in glucose metabolism.
J Mol Med (Berl). 2013 Jan;91(1):59-67. doi: 10.1007/s00109-012-0961-5. Epub 2012 Sep 27.
9
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
Nat Med. 2011 Jun 19;17(7):845-53. doi: 10.1038/nm.2370.
10
The heterozygote advantage of the Chuvash polycythemia VHLR200W mutation may be protection against anemia.
Haematologica. 2011 Sep;96(9):1371-4. doi: 10.3324/haematol.2011.045609. Epub 2011 May 23.
Zotero 插件